4D Molecular Therapeutics (FDMT) Projected to Post Earnings on Wednesday

4D Molecular Therapeutics (NASDAQ:FDMT) will likely be issuing its Q3 2025 results before the market opens on Wednesday, November 12th. Analysts expect the company to announce earnings of ($1.02) per share and revenue of $0.4030 million for the quarter. Individuals may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Friday, November 21, 2025 at 9:30 AM ET.

4D Molecular Therapeutics (NASDAQ:FDMT) last issued its quarterly earnings data on Monday, August 11th. The company reported ($0.98) earnings per share for the quarter, missing the consensus estimate of ($0.88) by ($0.10). 4D Molecular Therapeutics had a negative return on equity of 40.15% and a negative net margin of 594,375.81%.The business had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.52 million. On average, analysts expect 4D Molecular Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

4D Molecular Therapeutics Stock Down 3.8%

NASDAQ:FDMT opened at $10.50 on Monday. 4D Molecular Therapeutics has a 52 week low of $2.23 and a 52 week high of $12.34. The stock’s fifty day moving average is $8.91 and its two-hundred day moving average is $6.04. The company has a market capitalization of $490.37 million, a P/E ratio of -2.97 and a beta of 2.96.

Insider Activity at 4D Molecular Therapeutics

In other news, insider Scott Bizily sold 2,678 shares of the company’s stock in a transaction on Friday, October 24th. The stock was sold at an average price of $12.00, for a total transaction of $32,136.00. Following the sale, the insider owned 3,594 shares of the company’s stock, valued at approximately $43,128. This represents a 42.70% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold a total of 9,128 shares of company stock valued at $92,100 in the last three months. Insiders own 9.60% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Dynamic Technology Lab Private Ltd acquired a new stake in 4D Molecular Therapeutics in the first quarter valued at approximately $39,000. AQR Capital Management LLC acquired a new stake in shares of 4D Molecular Therapeutics in the 1st quarter valued at $46,000. Rangeley Capital LLC purchased a new stake in shares of 4D Molecular Therapeutics during the 2nd quarter worth $48,000. Russell Investments Group Ltd. lifted its position in shares of 4D Molecular Therapeutics by 11.7% during the 2nd quarter. Russell Investments Group Ltd. now owns 21,816 shares of the company’s stock worth $81,000 after purchasing an additional 2,284 shares during the last quarter. Finally, Bridgeway Capital Management LLC boosted its position in shares of 4D Molecular Therapeutics by 100.3% during the 2nd quarter. Bridgeway Capital Management LLC now owns 25,000 shares of the company’s stock worth $93,000 after acquiring an additional 12,516 shares in the last quarter. 99.27% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on FDMT shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research report on Wednesday, October 8th. Morgan Stanley raised shares of 4D Molecular Therapeutics from an “underweight” rating to an “equal weight” rating in a research note on Friday. Royal Bank Of Canada restated an “outperform” rating and issued a $26.00 price objective on shares of 4D Molecular Therapeutics in a report on Tuesday, October 21st. Roth Capital lowered their price objective on shares of 4D Molecular Therapeutics from $44.00 to $38.00 and set a “buy” rating for the company in a research report on Tuesday, August 12th. Finally, Chardan Capital reiterated a “buy” rating and issued a $25.00 target price on shares of 4D Molecular Therapeutics in a report on Tuesday, August 12th. Eight investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $28.50.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.